Table 2 Multivariate cox analysis of immune risk score and clinical variables in training dataset, validation dataset-1 and validation dataset-2
From: An individualized immune prognostic signature in lung adenocarcinoma
Training dataset HR (95% CI) | p value | Validation dataset-1 HR (95% CI) | p value | Validation dataset-2 HR (95% CI) | p value | |
|---|---|---|---|---|---|---|
IRS | 10.71 (5.72–20.07) | < 0.01 | 2.68 (1.15–6.27) | 0.02 | 3.71 (1.33–10.33) | 0.01 |
Age | 1.03 (1.02–1.05) | < 0.01 | 1.03 (1.01–1.04) | < 0.01 | 1.00 (0.98–1.03) | 0.65 |
Gender male | 1.08 (0.81–1.44) | 0.60 | 1.22 (0.93–1.59) | 0.14 | 1.69 (1.14–2.51) | < 0.01 |
Stage | ||||||
I | Reference | |||||
II | 2.12 (1.56–2.89) | < 0.01 | 1.85 (1.28–2.69) | < 0.01 | 2.13 (1.30–3.51) | < 0.01 |
III | 2.52 (1.38–4.59) | < 0.01 | 5.57 (3.66–8.48) | < 0.01 | 3.37 (2.05–5.54) | < 0.01 |
IV | 2.58 (0.82–8.18) | 0.11 | NA | NA | 4.02 (1.78–9.08) | < 0.01 |
Purity | 1.31 (0.48–3.53) | 0.60 | 1.41 (0.52–3.85) | 0.50 | 0.95 (0.23–3.91) | 0.95 |